Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24784061 | 0.86 | GNAO1 (0.42) | ARG1ARG2CHRM4GNAO1SIGMAR1 | |
| SCHEMBL23105099 | 0.84 | ARG1 (0.40) | ARG1ARG2CHRM4NOS3NOS1 | |
| SCHEMBL23946081 | 0.81 | ARG1 (0.41) | ARG1ARG2CHRM4GNAO1NPY1R | |
| SCHEMBL23373022 | 0.80 | PIK3CD (0.39) | — | |
| SCHEMBL18389282 | 0.80 | ARG1 (0.37) | ARG1ARG2CHRM4NOS3NOS1 | |
| SCHEMBL10052292 | 0.80 | ARG1 (0.37) | ARG1ARG2CHRM4NOS3NOS1 | |
| SCHEMBL7320753 | 0.79 | SIGMAR1 (0.43) | ARG1ARG2CHRM4SIGMAR1 | |
| SCHEMBL22600148 | 0.79 | ARG1 (0.35) | ARG1ARG2CHRM4NOS3NOS1 | |
| SCHEMBL20805135 | 0.78 | ARG1 (0.45) | ARG1ARG2NOS3NOS1NOS2 | |
| SCHEMBL22817568 | 0.78 | ARG1 (0.36) | ARG1ARG2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | ARG1 3500/4885ARG2 2356/4885CHRM4 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.